MTOR and neoplasm: Several key pathways are implicated in SCLC progression and tumor-endothelial interactions, most notably notch receptor (NOTCH), mechanistic target of rapamycin kinase (mTOR) and mitogen-activated protein kinase (MAPK) signaling pathways[2,17].